Skip to main content
SpringerLink
Log in

Discovery of Boceprevir, a Ketoamide-Derived HCV NS3 Protease Inhibitor, for Treatment of Genotype 1 Infections

  • Chapter
  • First Online:
HCV: The Journey from Discovery to a Cure

Part of the book series: Topics in Medicinal Chemistry ((TMC,volume 31))

Abstract

Blood-borne hepatitis C infections are the primary cause for liver cirrhosis and hepatocellular carcinoma. Prior to the discovery of direct-acting antiviral agents, the only treatment option was a regimen of interferon and ribavirin. It was modestly effective with only ~40% of genotype 1 patients demonstrating sustained virologic response. It was also accompanied with severe side effects with flu-like symptoms and increased suicidal tendencies during treatment. Advances in understanding the life cycle of the virus identified many potential novel drug targets that could be inhibited with small-molecule inhibitors. HCV NS3 protease, a serine enzyme, was identified as an important target for development of inhibitors because it was involved in processing of HCV-encoded polypeptide at multiple sites. The team resorted to a structure-based design because high-throughput screening with multiple compound libraries did not result in any starting point for SAR optimization. Introduction of electrophilic traps to natural substrate of the enzyme identified a ketoamide-derived undecapeptide lead. It was optimized to identify the first ketoamide-derived direct-acting antiviral agent for the treatment of HCV gt-1 infections approved by FDA. The following chapter describes the discovery of the undecapeptide lead and optimization of the scaffold to discover boceprevir for the treatment of HCV gt-1 infections.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 349.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 449.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 449.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Freeman AJ, Dore GJ, Law MG, Thorpe M, Overbeck JV, Llyods AR, Marinos G, Kaldor JM (2001) Estimating progression to cirrhosis in chronic hepatitis C infection. Hepatology 34:809–816

    Article  CAS  Google Scholar 

  2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M-H, Albrecht JK, International Hepatitis Interventional Therapy Group (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358:958–965

    Article  CAS  Google Scholar 

  3. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai M-Y, Gane E, O’Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343(23):1666–1172

    Article  CAS  Google Scholar 

  4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359–362

    Article  CAS  Google Scholar 

  5. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo M, Lee W-S, Kuo C, Berger K, Shuster JR, Overby LR, Bradley W, Houghton M (1989) An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362–364

    Article  CAS  Google Scholar 

  6. Bartenschlager R (1999) The NS3/4A proteinase of the hepatitis C virus: unraveling structure and function of an unusual enzyme and a prime target for antiviral therapy. J Virol Hepatitis 6:165–181

    Article  CAS  Google Scholar 

  7. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H (1993) Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 67:3835–3844

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M, Steinkuehler C, Tomei L, De-Francesco R, Kuo LC, Chen Z (1998) Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 Å resolution structure in a hexagonal crystal form. Protein Sci 7:837–847

    Article  CAS  Google Scholar 

  9. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Hostomska Z (1996) The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87:331–342

    Article  CAS  Google Scholar 

  10. Kim JL, Morgenstern KA, Griffith JP, Dweyer MD, Thomson JA, Murcko MA, Lin C, Caron PR (1998) Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 6:89–100

    Article  CAS  Google Scholar 

  11. Urbani A, Bianchi E, Narjes F, Tramontano A, De Francesco R, Steinkuhler C, Pessi A (1997) Substrate specificity of the hepatitis C virus serine protease NS3. J Biol Chem 272:9204–9209

    Article  CAS  Google Scholar 

  12. Kolykhalov AA, Agapov EV, Rice CM (1994) Specificity of the hepatitis C virus NS3 serine protease: effects of substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B cleavage sites on polyprotein processing. J Virol 68:7525–7533

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Zhang R, Beyer BM, Durkin J, Ingram R, Njoroge FG, Windsor WT, Malcolm BA (1999) A continuous spectrophotometric assay for the hepatitis C virus serine protease. Anal Biochem 270:268–275

    Article  CAS  Google Scholar 

  14. Lohmann V, Körner F, Koch J-O, Herian U, Theilmann L, Bartenschlager R (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110–113

    Article  CAS  Google Scholar 

  15. Mamai A, Zhang R, Natarajan A, Madalengoitia JS (2001) Poly-L-proline type-II peptide mimics based on the 3-azabicyclo[3.1.0]hexane system. J Org Chem 66:455–460

    Article  CAS  Google Scholar 

  16. Bogen SL, Arasappan A, Bennett F, Chen K, Jao E, Liu Y-T, Lovey RG, Venkatraman S, Pan W, Parekh T, Pike RE, Ruan S, Liu R, Baroudy B, Agrawal S, Chase R, Ingravallo P, Pichardo J, Prongay A, Brisson J-M, Hsieh TY, Cheng K-C, Kemp SJ, Levy OE, Lim-Wilby M, Tamura SY, Saksena AK, Girijavallabhan V, Njoroge FG (2006) Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J Med Chem 49:2750–2757

    Article  CAS  Google Scholar 

  17. Cox KA, Dunn-Meynell K, Korfmacher W, Broske L, Nomeir AA, Lin CC, Cayen MN, Barr WH (1999) Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats. Drug Discov Today 4:232–237

    Article  CAS  Google Scholar 

  18. Venkatraman S, Bogen SL, Arasappan A, Bennett F, Chen K, Jao E, Liu Y-T, Lovey R, Hendrata S, Huang Y, Pan W, Parekh T, Pinto P, Popov V, Pike R, Ruan S, Santhanam B, Vibulbhan B, Wu W, Yang W, Kong J, Liang X, Wong J, Liu R, Butkiewicz N, Chase R, Hart A, Agarwal S, Ingravallo P, Pichardo J, Kong R, Baroudy B, Malcolm B, Guo Z, Prongay A, Madision BL, Cui X, Cheng K-C, Hsieh TY, Brisson J-M, Prelusky D, Kormacher W, White R, Bogonowich-Knipp S, Pavlovsky A, Prudence B, Saksena AK, Ganguly A, Piwinski J, Girijavallabhan V, Njoroge FG (2006) Discovery of (1R, 5 S )-N-[3-amino-1-(cyclobutylmethyl)-2-3-dioxopropyl]-3-[2(S )-[[[(1,1-dimethylethyl)-amino]carbonyl]amio]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S )-carboxamide (SCH 503034), a selective, potent, orally bioavailable, hepatits C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 49:6074–6086

    Article  CAS  Google Scholar 

  19. Malcolm BA, Liu R, Lahser F, Agrawal D, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, Hesk D, Ingravallo P, Jiang C, Kong R, Lu J, Pichardo J, Prongay A, Skelton A, Tong X, Venkatraman S, Xia E, Girijavallabhan V, Njoroge FG (2006) Sch 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicob Agents Chemother 50:1013–1020

    Article  CAS  Google Scholar 

  20. Cheng K-C, Li C, Liu T, Wang G, Hsieh Y, Pavlovsky A, Broske L, Prelusky D, Chen J, Liu R, Uss AS, White RE, Gupta S, Njoroge FG (2009) Use of preclinical invitro and in vivo pharmacokinetics for selection of potent hepatitis C protease inhibitor, Boceprevir for clinical development. Lett Drug Des Discov 6:312–218

    Article  CAS  Google Scholar 

  21. Tong X, Guo Z, Wright-Minogue J, Xia E, Prongay A, Madison V, Qiu P, Venkatraman S, Velazquez F, Njoroge FG, Malcolm BA (2006) Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochem J 45:1353

    Article  CAS  Google Scholar 

  22. Guo Z, Prongay A, Tong X, Thierry F, Bogen S, Velazquez F, Venkatraman S, Njoroge FG, Madison V (2006) Computational study of the effects of mutations A156T, D168V, and D168Q on the binding of HCV protease inhibitors. J Comput Chem 2:1657

    CAS  Google Scholar 

  23. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA (2006) Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70:28–38

    Article  CAS  Google Scholar 

  24. Barnard RJ, Howe JA, Ogert RA, Zeuzem S, Poordad F, Gordon SC, Ralston R, Tong X, Sniukiene V, Strizki J, Ryan D, Long J, Qiu P, Brass CA, Albrecht J, Burroughs M, Vuocolo S, Hazuda DJ (2013) Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virol J 444:329–336

    Article  CAS  Google Scholar 

  25. Prongay AJ, Guo Z, Yao N, Pichardo J, Fischmann T, Strickland C, Myers J Jr, Weber PC, Beyer BM, Ingram R, Hong Z, Prosise WW, Ramanathan L, Taremi SS, Yarosh-Tomaine T, Zhang R, Senior M, Yang RS, Malcolm B, Arasappan A, Bennett F, Bogen SL, Chen K, Jao E, Liu Y-T, Lovey RG, Saksena AK, Venkatraman S, Girijavallabhan V, Njoroge FG, Madison V (2007) Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034). Key steps in structure-based optimization. J Med Chem 50:2310–2318

    Article  CAS  Google Scholar 

  26. Bacon B, Gordon SC, Lawitz E, Marcellin P, Vierling J;M, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R (2011) For the HCV RESPOND-2 investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364(13):1207–1217

    Article  CAS  Google Scholar 

  27. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK, On Behalf of the SPRINT-1 Investigators (2010) Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicenter phase 2 trial. Lancet 376:705–716

    Article  CAS  Google Scholar 

  28. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki J-P (2011) For the SPRINT-2 investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364(13):1195–1206

    Article  CAS  Google Scholar 

Download references

Compliance with Ethical Standards

Conflict of Interest: Dr. Srikanth worked for Schering /Merck.

Ethical Approval: This article does not contain any studies with human participants or animals performed by any of the authors.

Author information

Authors and Affiliations

  1. Disc Medicine, Cambridge, MA, USA

    Srikanth Venkatraman

Authors
  1. Srikanth Venkatraman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Srikanth Venkatraman .

Editor information

Editors and Affiliations

  1. Arbutus Biopharma, Inc., Warminster, PA, USA

    Michael J. Sofia

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Venkatraman, S. (2019). Discovery of Boceprevir, a Ketoamide-Derived HCV NS3 Protease Inhibitor, for Treatment of Genotype 1 Infections. In: Sofia, M. (eds) HCV: The Journey from Discovery to a Cure. Topics in Medicinal Chemistry, vol 31. Springer, Cham. https://doi.org/10.1007/7355_2018_40

Download citation

Publish with us

Policies and ethics

Search

Navigation